Status:
COMPLETED
Dose Ranging Study With LT, Monotherapy, PPAR
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Diabetes Mellitus II
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
PHASE3
Brief Summary
A Randomized, Double-Blind, Dose-Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects with Type 2 Diabetes
Eligibility Criteria
Inclusion
- 1\. HbA1c \> 7.0% and ≤ 10.0% obtained at the Screening visit.
- 2\. Men and women, 18-70 years of age Established Type 2 diabetes
Exclusion
- 1\. Symptomatic Type 2 diabetes defined as marked polyuria and polydipsia with greater than 10% weight loss during the last three months.
- 2\. Administration of antihyperglycemic agents (other than thiazolidinediones) for more than three consecutive or a total of seven non-consecutive days during the four weeks prior to screening.
- 3\. Administration of thiazolidinediones for more than three consecutive or a total of seven non-consecutive days during the six weeks prior to screening.
Key Trial Info
Start Date :
May 1 2002
Trial Type :
INTERVENTIONAL
End Date :
June 1 2006
Estimated Enrollment :
1260 Patients enrolled
Trial Details
Trial ID
NCT00240383
Start Date
May 1 2002
End Date
June 1 2006
Last Update
September 14 2010
Active Locations (272)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Anniston, Alabama, United States
2
Local Institution
Birmingham, Alabama, United States
3
Local Institution
Huntsville, Alabama, United States
4
Local Institution
Hot Springs, Arizona, United States